Tags

Type your tag names separated by a space and hit enter

The effect of nimodipine, a centrally active calcium antagonist, on visual function and mascular blood flow in patients with normal-tension glaucoma and control subjects.
J Glaucoma 1998; 7(5):336-42JG

Abstract

PURPOSE

This study was performed to evaluate the effect of nimodipine, a centrally active calcium channel antagonist on automated Humphrey visual fields, Farnsworth-Munsell 100 (FM-100) hue color vision testing, and macular blood flow (blue field entoptic simulation technique) in patients with normal-tension glaucoma (NTG) and control subjects.

METHODS

Thirteen patients with NTG and thirteen age- and sex-matched control subjects were studied in a prospective, placebo-controlled, double-masked, crossover protocol. On each of the two study dates, testing was performed at baseline and 90 minutes after administration of either two 30-mg nimodipine capsules or two identical appearing placebo capsules. Blood pressure and pulse were monitored throughout the study.

RESULTS

Nimodipine administration resulted in a performance corrected improvement in Humphrey visual field mean deviation (patients with NTG and control subjects), corrected pattern standard deviation (patients with NTG), and macular sensitivity (the average of the foveal threshold and the four most central points of the visual field; patients with NTG). The FM-100 hue error scores significantly decreased after administration of nimodipine in patients with NTG and control subjects compared with baseline. There were no significant differences in baseline leukocyte velocity or density between patients with NTG and control subjects; no significant changes in leukocyte velocity or density were noted after administration of nimodipine in either group.

CONCLUSION

Nimodipine caused a significant performance corrected improvement in visual field testing and a significant improvement in color vision. Nimodipine did not alter macular hemodynamics as measured using the blue field entoptic simulation technique, although results were hampered by high variability, particularly in the leukocyte density measurements.

Authors+Show Affiliations

Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania School of Medicine, Philadelphia, USA.

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

9786563

Citation

Piltz, J R., et al. "The Effect of Nimodipine, a Centrally Active Calcium Antagonist, On Visual Function and Mascular Blood Flow in Patients With Normal-tension Glaucoma and Control Subjects." Journal of Glaucoma, vol. 7, no. 5, 1998, pp. 336-42.
Piltz JR, Bose S, Lanchoney D. The effect of nimodipine, a centrally active calcium antagonist, on visual function and mascular blood flow in patients with normal-tension glaucoma and control subjects. J Glaucoma. 1998;7(5):336-42.
Piltz, J. R., Bose, S., & Lanchoney, D. (1998). The effect of nimodipine, a centrally active calcium antagonist, on visual function and mascular blood flow in patients with normal-tension glaucoma and control subjects. Journal of Glaucoma, 7(5), pp. 336-42.
Piltz JR, Bose S, Lanchoney D. The Effect of Nimodipine, a Centrally Active Calcium Antagonist, On Visual Function and Mascular Blood Flow in Patients With Normal-tension Glaucoma and Control Subjects. J Glaucoma. 1998;7(5):336-42. PubMed PMID: 9786563.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of nimodipine, a centrally active calcium antagonist, on visual function and mascular blood flow in patients with normal-tension glaucoma and control subjects. AU - Piltz,J R, AU - Bose,S, AU - Lanchoney,D, PY - 1998/10/24/pubmed PY - 1998/10/24/medline PY - 1998/10/24/entrez SP - 336 EP - 42 JF - Journal of glaucoma JO - J. Glaucoma VL - 7 IS - 5 N2 - PURPOSE: This study was performed to evaluate the effect of nimodipine, a centrally active calcium channel antagonist on automated Humphrey visual fields, Farnsworth-Munsell 100 (FM-100) hue color vision testing, and macular blood flow (blue field entoptic simulation technique) in patients with normal-tension glaucoma (NTG) and control subjects. METHODS: Thirteen patients with NTG and thirteen age- and sex-matched control subjects were studied in a prospective, placebo-controlled, double-masked, crossover protocol. On each of the two study dates, testing was performed at baseline and 90 minutes after administration of either two 30-mg nimodipine capsules or two identical appearing placebo capsules. Blood pressure and pulse were monitored throughout the study. RESULTS: Nimodipine administration resulted in a performance corrected improvement in Humphrey visual field mean deviation (patients with NTG and control subjects), corrected pattern standard deviation (patients with NTG), and macular sensitivity (the average of the foveal threshold and the four most central points of the visual field; patients with NTG). The FM-100 hue error scores significantly decreased after administration of nimodipine in patients with NTG and control subjects compared with baseline. There were no significant differences in baseline leukocyte velocity or density between patients with NTG and control subjects; no significant changes in leukocyte velocity or density were noted after administration of nimodipine in either group. CONCLUSION: Nimodipine caused a significant performance corrected improvement in visual field testing and a significant improvement in color vision. Nimodipine did not alter macular hemodynamics as measured using the blue field entoptic simulation technique, although results were hampered by high variability, particularly in the leukocyte density measurements. SN - 1057-0829 UR - https://www.unboundmedicine.com/medline/citation/9786563/The_effect_of_nimodipine_a_centrally_active_calcium_antagonist_on_visual_function_and_mascular_blood_flow_in_patients_with_normal_tension_glaucoma_and_control_subjects_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=9786563.ui DB - PRIME DP - Unbound Medicine ER -